ClearView Shareholders Back Zurich Takeover Scheme with Over 97% Proxy Support

Strong Shareholder Backing at Scheme Meeting

ClearView Wealth Limited (ASX:CVW) convened its Scheme Meeting on 27 July 2026, where shareholders overwhelmingly supported Zurich Financial Services Australia Limited’s proposed acquisition via a members’ scheme of arrangement. Proxy votes in favour of the Scheme Resolution accounted for nearly 98%, underscoring broad investor endorsement ahead of the next regulatory hurdle.

The ClearView Board, led by Chairman Geoff Black and Managing Director Nadine Gooderick, reiterated its unanimous recommendation for shareholders to vote in favour, contingent on no superior proposal emerging and the Independent Expert maintaining a positive assessment. Directors holding shares committed to voting their stakes in favour, reflecting confidence in the transaction.

Deal Terms and Special Dividend Impact

Under the Scheme, ClearView shareholders will receive $0.65 cash per share, subject to a reduction to $0.60 if a fully franked $0.05 special dividend is paid upon Scheme effectiveness. This special dividend, announced days before the meeting, is designed to enhance shareholder value when factoring in franking credits, potentially lifting the total consideration to approximately $0.67 per share for eligible investors.

The dividend and Scheme Consideration adjustments are embedded in the Scheme Implementation Deed, ensuring shareholders receive a combined cash payment of $0.65 per share across the special dividend and Scheme consideration dates. The ability to utilise franking credits depends on individual tax circumstances, adding a layer of complexity to the total value proposition.

Independent Expert Confirms Fairness of Offer

Grant Thornton, appointed as the Independent Expert, concluded the Scheme is fair and reasonable, valuing ClearView shares on a control basis between $0.625 and $0.764. The Scheme Consideration of $0.65 per share sits comfortably within this range, providing a valuation anchor that supports the Board’s recommendation.

This expert endorsement is a critical component, reassuring shareholders that the offer reflects an equitable price given ClearView’s standalone prospects and market conditions.

Conditions and Timeline Ahead

While shareholder approval at the Scheme Meeting marks a significant milestone, the transaction remains subject to customary conditions, including Supreme Court approval scheduled for 30 July 2026. Assuming court endorsement, the Scheme will become effective on 31 July, triggering the suspension of ClearView shares from ASX trading.

Key dates following effectiveness include the special dividend record date on 5 August, dividend payment on 12 August, Scheme record date on 13 August, and final Scheme implementation with cash consideration payment on 20 August. These milestones chart a clear path to completion, barring unforeseen delays.

Balancing Certainty and Strategic Options

The Board acknowledges the merits of ClearView’s standalone strategy but views the Scheme as offering shareholders attractive certainty of value and liquidity, mitigating exposure to business risks inherent in the wealth management sector. The absence of any superior proposal to date further consolidates the case for approval.

For shareholders hesitant about relinquishing direct investment or concerned about tax implications, the Scheme Booklet outlines potential drawbacks and alternative considerations, ensuring informed decision-making.